Similar Datasets
Project description:The objective of the study was to examine the gene expression changes in glioma cell line U87 and U251 with LAMP2A knockdown. There were 15 samples in total- U87-1, U87-2, U87-3, U87-1812-1, U87-1812-2, U87-1812-3, U251-1, U251-2, U251-3, U251-1812-1, U251-1812-2, U251-1812-3, U251-1813-1, U251-1813-2, and U251-1813-3. U87-1 to U87-3 and U251--1 to U251-3 were used as the control groups (CON). U87-1812-1 to U871812-3, U251-1812-1 to U251-1812-3, and U251-1813-1 to U251-1813-3 were used as the experimental groups (shLAMP2A-1 and shLAMP2A-2). The total RNA of each sample was extracted from the stable transfected glioma cells by using TRIzol reagent. Then the RNA samples were processed for high throughput transcriptome sequencing on Illumina HiSeq 3000 platform. There were two types of libraries: the circRNA, mRNA, and lncRNA were all constructed by removing rRNA (one library, three types of RNA were analyzed together), and the insert fragment was about 300bp; the small RNA was constructed and analyzed separately, mainly microRNA of about 22bp. Results: among 60612 cleaned mRNAs, 781 were differentially expressed in U87-1812 group compared with U87 group, 146 were differentially expressed in U251-1812 group compared with U251 group, 43 were differentially expressed in U251-1813 group compared with U251 group (padj ≤ 0.05 and expression change ≥2 fold). The differential expressed genes distributed in all chromosomes. Functional annotation with GO and KEGG enrichment revealed the top functional groups including inflammation, DNA replication, cell adhesion, TNF, IL17, and axon guidance signaling pathways.
2024-07-15 | GSE270618 | GEO
Project description:Glioma is a malignant primary tumour that occurs in the central nervous system. TEA domain transcription factor (TEAD) family proteins are the Hippo pathway's ultimate effector molecules. The function of TEAD3 in gliomas is still unclear. Therefore, RNA sequencing was performed on TEAD3 knockdown U251 cells and normal U251 cells. The samples in this study included normal U251 control group and TEAD3 knockdown group. Each group contained three samples. Total RNA was extracted using Trizol reagent following the manufacturer's procedure. The total RNA quantity and purity were analysis of Bioanalyzer 2100 and RNA 6000 Nano LabChip Kit, high-quality RNA samples with RIN number > 7.0 were used to construct sequencing library. Gene Set Enrichment Analysis (GSEA) based on the sequencing results showed that knockdown of TEAD3 in the U251 cell line caused changes in several important pathways, including CTLA4 inhibitory pathway, defective pyroptosis, signaling by Hippo, regulation of TP53 activity, E2F mediated regulation of DNA replication, and FCGR3A mediated phagocytosis.
2023-01-25 | GSE223378 | GEO
Project description:RNAseq analysis of U251 cell line treated with 100nM of LLY-283 compared to Vehicle treated cells to analyse the effect of LLY-283 on gene expression and mRNA splicing.
2024-08-02 | GSE264609 | GEO
Project description:The expression profiling of a total of 34181 mRNAs in 3 paired U251 cell line, which had been stable knockdown the expression of LINC01116.
2018-08-31 | GSE103455 | GEO
Project description:PD-L1 (CD274) overexpression effect on glioblastoma cell line U251
| PRJNA420727 | ENA
Project description:This study investigated the molecular mechanisms of specific medium chain fatty acids in a cellular model of cancer. These fatty acids are provided in the medium chain triglyceride (MCT) ketogenic diet, that is a widely used treatment for patients with drug resistant epilepsy, where the diet is commonly considered to function through the production of ketones. Ketogenic diets are also increasingly being investigated for the treatment of various cancers. One recent advance in the field was the identification of several therapeutic mechanisms for one of these fatty acids, decanoic acid, independent of ketosis. In addition, a recent clinical trial of a new MCT blend containing elevated levels of decanoic acid provided seizure control without ketosis, confirming a ketone-independent therapeutic mechanism. The cellular role of this new MCT blend in cancer treatment has not been examined. Here, we investigate decanoic acid and the new MCT blend on cancer cell biology using U251 cells, a human glioblastoma-derived cancer line, treated in culture with therapeutically relevant concentrations of decanoic acid and the new MCT blend, for a period of time that has been shown to trigger metabolic changes in patients. The cellular mechanism of these medium chain fatty acids where then investigated a proteomic level.
2026-05-25 | PXD068251 | Pride
Project description:miRNAseq of chronic lymphocytic leukaemia (CLL) subsets comprising of Unmutated CLL and Mutated CLL. Mutated CLL cases were further subdivided based on B cell receptor signalling capacity.
2023-05-11 | E-MTAB-12017 | biostudies-arrayexpress
Project description:mRNA sequence of the glioma cell line U251 after TEAD3 knockdown
| PRJNA925896 | ENA